Therefore, from our combined findings on IL-6, IL6R, and IL6ST, it can be concluded that a higher baseline level of IL-6 has protective effects against COVID-19, and in the presence of higher levels of IL-6 signaling inhibitors, like soluble IL6ST, a delay in the effective immune response leads to the exacerbation of the disease. This evidence concerns the gene IL6 and COVID-19.